Everything drug pricing and policy, every day
And there was a ton of obesity-price coverage over the weekend, but I’m not sure anyone learned anything
And lots of links from the journals today, including how to get payers to listen to patients, CivicaScript’s case study, and Medicaid drug spending
And PhRMA and PBMs offer competing takes on MFN
And trying to figure out which countries are in and which are out in the administration’s MFN calculus
And ICER details how it will look at launch prices
Plus links on the reality of PBMs in 2025 and the current state of the reconciliation bill (that is actually a PBM-reform bill)
And new work from NPC suggests that the IRA disincentives in orphan drugs are -- unfortunately -- impacting development
And introducing a new Apex resource: the List- and Net-Price Disclosures spreadsheet
And when it comes to drug pricing, can you tell a Trump quote from a Bernie quip?
